Filing Flows › AIM ImmunoTech (AIM) › R&D spending
AIM ImmunoTech (AIM) R&D spending by quarter
AIM ImmunoTech's R&D spending was $589K in Q2 2026 (second quarter 2026), +22% from Q1 2026. Over the last 7 quarters it ranged from $482K (Q1 2026) to $1.7M (Q4 2024).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $589K | +22% | -50% |
| Q1 2026 | $482K | -55% | -55% |
| Q4 2025 | $1.1M | +75% | -36% |
| Q3 2025 | $607K | -48% | — |
| Q2 2025 | $1.2M | +9% | — |
| Q1 2025 | $1.1M | -35% | — |
| Q4 2024 | $1.7M | — | — |
Q2 2026 at a glance
AIM ImmunoTech, Q2 2026: revenue $26K (+4% year over year), net loss $3.8M, operating cash flow −$4.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is AIM ImmunoTech's R&D spending?
AIM ImmunoTech's R&D spending was $589K in Q2 2026 (second quarter 2026), +22% from Q1 2026.
How has AIM ImmunoTech's R&D spending changed?
Over the last 7 quarters it ranged from $482K (Q1 2026) to $1.7M (Q4 2024).